MiNK Therapeutics Scheduled to Report Q3 2026 Earnings
MiNK Therapeutics (INKT) is set to release its third-quarter 2026 financial results on Wednesday, November 11th, prior to the U.S. market open. The company's performance will be closely watched following recent updates regarding clinical enrollment for Acute Respiratory Distress Syndrome (ARDS) in the United States. Market analysts have established a consensus EPS estimate of -$0.50 and a revenue projection of $0.15 million. Recent sentiment among analysts shows slight downward pressure, with one downward revision to earnings per share estimates over the last three months and no upward revisions recorded.
Tickers: $INKT
Topics: biotechnology earnings release schedule EPS estimates revenue estimates